POST Online Media Lite Edition


AstraZeneca buys factory in Boulder, Colorado

Staff writer |
AstraZeneca added to its biologics manufacturing capability in the U.S. with the purchase of a high-tech biologics bulk manufacturing facility from Amgen.

Article continues below

Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.

AstraZeneca plans to start staffing the facility immediately to support refurbishment and infrastructure improvements.

Once complete, the site is expected to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations.

In the longer term, this site could create up to 400 highly skilled jobs, subject to relevant approvals by the local authorities. The facility will eventually double the biologics manufacturing capacity in the US to meet the needs of the maturing AstraZeneca pipeline.

Currently biologics make up 50 percent of the company’s pipeline with more than 120 ongoing programmes, including over 30 in clinical development.

The financial details were not disclosed. This investment does not impact AstraZeneca’s financial guidance for 2015.

What to read next

Pfizer officially withdraws from AstraZeneca deal
Astrazeneca agrees sale of migraine treatment to Grunenthal for $200m plus $102m
AstraZeneca sells Crohn's disease and ulcerative colitis medicine rights